Compare Toronto-Dominion Bank (TD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs TG Therapeutics Inc — how do they compare? Toronto-Dominion Bank trades at $119.14 (market cap $197.22B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Toronto-Dominion Bank is far larger — about 23.1× TG Therapeutics Inc's market cap, and Toronto-Dominion Bank pays a 2.69% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TD | TGTX | |
|---|---|---|
Market Cap | $197.22B | $8.53B |
Sector | Financials | Health |
52-Week High | $124.80 | $59.06 |
52-Week Low | $75.86 | $26.94 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $120.52, down 0.91% today, with a neutral technical signal. The company reported strong Q3 2026 earnings, beating estimates with a profit of $4.62 billion, driven by capital markets and cost controls. Revenue growth is steady, with 2025 revenue at $61.28 billion and net income margin of 24.88%. Analyst consensus is bullish with 9 buy ratings and no sells. Recent news highlights AI value generation and participation in tokenized payments tests.
Outlook remains positive given earnings momentum and dividend stability, but risks include high debt levels and macroeconomic sensitivity. The stock offers value with a P/E of 17.85 and consistent dividend payments, though competition and interest rate fluctuations pose challenges.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
